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Purpose: Matrix metalloproteinases (MMPs) play an essential role in the turnover of the extracellular matrix and cellular
behavior. MMP1, MMP2, and MMP9 have previously been implicated in the pathogenesis of primary open angle glaucoma
(POAG)  and  open  angle  glaucoma  secondary  to  exfoliation  syndrome  (XFG),  respectively.  Functional  gene
polymorphisms of these MMPs such as MMP1 −1607 1G/2G (rs1799750), MMP2 −1306 C/T (rs243865), MMP2 −1575
G/A (rs243866), and MMP9 Q279R (rs17576) are thus plausible candidates as risk factors for open angle glaucomas. The
purpose of the present study was to investigate hypothesized associations between these polymorphisms and the presence
of POAG and XFG in a Caucasian population.
Methods: The present case-control study included 322 patients with POAG, 202 patients with XFG, and 248 control
subjects. Genotyping of polymorphisms was done using polymerase chain reaction.
Results: No significant differences in either genotype distributions or allelic frequencies of MMP1 −1607 1G/2G,
MMP2 −1306 C/T, MMP2 −1575 G/A, and MMP9 Q279R were found between patients with POAG and control subjects
and patients with XFG and control subjects, respectively (p>0.05). The presence of POAG or XFG was not predicted by
any of the investigated polymorphisms.
Conclusions: Our data suggest that the MMP1 −1607 1G/2G, MMP2 −1306 C/T, MMP2 −1575 G/A, and MMP9 Q279R
polymorphisms themselves are unlikely major risk factors among Caucasian patients with either POAG or XFG.
Primary open angle glaucoma (POAG) and open angle
glaucoma  secondary  to  exfoliation  syndrome  (XFG)  are
among the main causes of irreversible blindness worldwide
[1].  They  are  characterized  by  progressive  loss  of  retinal
ganglion cells (RGCs) and their respective axons leading to
the  pathognomonic  cupping  of  the  optic  nerve  head  [2].
Although  an  elevated  intraocular  pressure,  as  a  result  of
alterations in the trabecular meshwork (TM), remains the most
important and presently only therapeutically modifiable risk
factor,  other  risk  factors  including  vascular,  excitotoxic,
neurotoxic, or genetic factors have been reported [3-5]. The
impact of genetic factors has been studied with great effort
leading to the identification of several mutations and gene
polymorphisms as risk factors. Mutations in the myocilin gene
(MYOC) in the case of POAG and as for XFG polymorphisms
in the lysyl oxidase like protein 1 (LOXL1) gene are the most
prominent  among  them  [6-16].  However,  mutations  in
MYOC are not found in most of patients with POAG and many
individuals with polymorphisms in LOXL1 do not develop
exfoliation syndrome or XFG [17,18]. Therefore, other as yet
unknown genetic factors might also play a pathogenetic role
in these entities.
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Matrix metalloproteinases (MMPs) comprise a family of
at least 25 secreted zinc proteinases, which are of eminent
importance  not  only  for  the  extracellular  matrix  (ECM)
turnover, but also for interactions between cells and their
sorrounding [19]. They have been linked to many physiologic
as well pathologic events (i.e., embryogenesis, wound healing
and  tissue  remodeling,  inflammation,  angiogenesis,
carcinogenesis).  Not  surprisingly,  MMPs  have  also  been
demonstrated  to  exert  pathogenetic  effects  in  POAG  and
XFG. In a human outflow model injection of MMP2, MMP3,
and MMP9 led to a significantly increased outflow facility
[20], furthermore in an in vitro study using porcine TM cells
mechanical stress increased MMP2 and MMP14 expression
[21]. Interestingly, latanoprost has been suggested to exert its
effects on the remodeling of the ECM in the TM via MMP2
and  MMP3  [22].  In  patients  with  POAG  and  XFG
significantly altered levels of MMPs in the aqueous humor
have been described [23,24]. In the optic nerve heads of both
human  glaucomatous  eyes  and  monkey  eyes  with
experimental glaucoma increased expression of MMP1 has
been reported [25,26]. Furthermore, after optic nerve ligation
MMP9 expression in the mouse retina is increased leading to
apoptotic ganglion cell loss [27].
Generally, activity of MMPs is regulated at the level of
expression, posttranslational activation, and inhibition [19].
With  regard  to  expression  of  MMPs  common  functional
polymorphisms have been identified. In the promotor region
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1764of MMP1 an additional guanine at position −1607 (MMP1
−1607  1G/2G;  rs1799750)  leads  to  a  significantly  higher
transcription rate of the gene [28], while in the promotor
region  of  MMP2  a  C  to  T  transition  at  position  −1306
(MMP2 −1306 C/T; rs243865) as well as a G to A transition
at  position  −1575  (MMP2  −1575  G/A;  rs243866)  are
associated  with  reduced  transription  activity  [29,30].  A
nonsynonymous A to G transition in exon 6 of MMP9 leading
to a substitution of arginine by glutamine at position 279
(MMP9  Q279R;  rs17576)  has  been  shown  to  affect  the
substrate binding capacity [31-33]. Recently, an association
of MMP9 Q279R with acute primary angle closure glaucoma
in Taiwanese patients has been found. Two subsequent studies
conducted in Singapore and southern China were unable to
replicate this finding [34-36]. As for the MMP1 −1607 1G/2G
polymorphism, a Greek study showed a trend for association
with exfoliation syndrome [37].
Our  study  was  set  to  investigate  a  hypothesized
association  of  the  aforementioned  polymorphisms  with
POAG  and  XFG  in  a  Central  European  population  of
Caucasian descent.
METHODS
In the present case-control study we investigated a total of 772
unrelated Caucasian subjects comprising 322 patients with
POAG, 202 patients with XFG, and 248 control subjects. All
participants were seen at the Department of Ophthalmology,
Medical University Graz and gave written informed consent
before enrolment. The study was conducted in accordance
with the standards of the local Ethics Committee and the
National Gene Technology Act.
All patients underwent slit lamp biomicroscopy, testing
for  best  corrected  visual  acuity,  Goldmann  applanation
tonometry, gonioscopy, and standard automated perimetry
(Interzeag  Octopus  101,  program  G2)  or  –  in  cases  of
profoundly decreased visual acuity – Goldmann perimetry. In
all patients photographs of the optic disc were taken.
POAG was defined by an intraocular pressure before
initiation of a pressure-lowering therapy of at least 21 mmHg,
an  open  anterior  chamber  angle,  optic  disk  changes
characteristic  for  glaucoma  (notching,  thinning  of  the
neuroretinal rim, increased cup/disc ratio in relation to the
optic  disc  size),  visual  field  defects  characteristic  for
glaucoma (inferior or superior arcuate scotoma, nasal step,
paracentral scotoma), and absence of conditions leading to
secondary  glaucoma.  XFG  was  defined  by  an  intraocular
pressure before initiation of a pressure-lowering therapy of at
least 21 mmHg, an open anterior chamber angle, optic disk
changes, and visual field defects characteristic for glaucoma
and presence of typical exfoliation material on the anterior
lens capsule.
The control group consisted of 248 unrelated patients
with no morphological or functional damage indicative for
primary or secondary open angle or angle closure glaucoma.
Control subjects were admitted to our department for cataract
surgery.  All  participants  were  Caucasians  from  the  same
geographic  area  (Southern  Austria).  Individuals  with
significant co-morbidity for eye diseases (except cataract or
mild diabetic retinopathy) were excluded from the study.
Genotype determination: Venous blood was collected in
3  ml  EDTA  tubes.  DNA  was  extracted  form  peripheral
lymphocytes using the nucleic isolation kit: QIAamp DNA
Mini and Blood Kit (Qiagen, Venlo, Netherlands) following
the manufactures protocol and stored at −20 °C. Genotype
determination was performed using high-resolution melting
curve analysis on the LightCycler® 480 PCR system (Roche
Diagnostics  AG,  Risch,  Switzerland).  The  samples  were
amplified in duplicate 20 µl reactions using the Light Cycler
480 High Resolution Melting Master kit (Roche Diagnostics,
Wien, Austria) and analyzed on a LC480 instrument I (Roche
Diagnostics GmbH, Mannheim, Germany). The final reaction
mix contained 1× Master Mix, 3 mM MgCl2, 4 µM forward
and reverse primer (Table 1) and 50 ng of genomic DNA. For
PCR the following cycling conditions were chosen: one cycle
of 95 °C for 10 min followed by 45 cycles of 95 °C for 10 s,
58 °C-60 °C for 15 s depending on the SNP investigated (58 °C
-  MMP-9-rs17576,  60  °C  -  MMP-1-rs1799750,  MMP-2-
rs243865,  MMP-2-rs243866)  and  72  °C  for  20  s.  The
amplicons were then denatured at 95 °C for 1 min, cooled
down to 40 °C for 1 min and then melted from 65 °C to 95 °C
with 25 signal acquisitions per degree. To detect sequence
variations  the  Gene  Scanning  Software  v1.5  (Roche
Diagnostics GmbH) was used. Using the Auto Group mode
samples were automatically grouped because of their melting
curves.
Statistical analysis: Descriptive statistics were used to
calculate frequencies and percentages of discrete variables.
Continuous data are given as mean ±standard deviation (SD).
Means were compared using Mann–Whitney test. Proportions
of groups were compared by χ2 test. Odds ratio (OR) and 95%
confidence  interval  (95%CI)  were  calculated  by  logistic
regression. Assuming a codominant effect, genotypes were
coded as 0 (no variant allele, wildtype), 1 (one variant allele,
heterozygous genotype), or 2 (two variant alleles). Hardy–
Weinberg  equilibrium  has  been  calculated  using  HW
Diagnostics-Version  1.beta  (Fox  Chase  Cancer  Center,
Philadelphia, PA). Statistical analysis was done using the
SPSS statistical package (SPSS, version 17.0, Chicago, IL).
Power calculation was done using PS Power and Sample Size
Calculation software version 2.1.30 [38].
RESULTS
Our study included 322 patients with POAG (188 female and
134 male), 202 patients with XFG (112 female and 90 male),
and 248 control subjects (126 female and 122 male). Clinical
characteristics of patients and control subjects are shown in
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1765Table  2  and  Table  3.  Patients  with  POAG  had  a  mean
deviation of 12.3±6.4 dB, a mean loss of variance of 40.0±27.3
square decibel, while patients with XFG had a mean deviation
of 12.7±6.8 dB, a mean loss of variance of 36.5±22.1 square
decibel.
Genotype distributions or allelic frequencies of MMP1
−1607 1G/2G, MMP2 −1306 C/T, MMP2 −1575 G/A, and
MMP9 Q279R did not significantly differ between patients
with POAG and control subjects (Table 4).
Similarly, no significant differences in either genotype
distributions or allelic frequencies of MMP1 −1607 1G/2G,
MMP2 −1306 C/T, MMP2 −1575 G/A, and MMP9 Q279R
were found between patients with XFG and control subjects
(Table 5). In a logistic regression analysis, presence of either
POAG or XFG was not predicted by any of the investigated
polymorphisms (Table 6).
The observed genotype distributions did not deviate from
those predicted by the Hardy–Weinberg equilibrium.
DISCUSSION
Elevated intraocular pressure generated by increased outflow
resistance leading to apoptotic death of retinal ganglion cells
is the main risk factor in the pathogenesis of POAG and XFG.
Increased plaque-like material within the TM as well as loss
of  TM  cells  have  been  linked  to  the  increased  outflow
resistance [39,40], whereas glaucomatous RGC death occurs
by  apoptosis,  a  subacute  process  provoked  by  cellular
degradation  rather  than  disruption  [41,42].  The  exact
biochemical pathways, however, leading to accumulation of
ECM in the TM as well as apoptotic death of retinal ganglion
cells are not understood. In the last years diverse studies
provided  evidence  that  MMPs  may  be  involved  in  both
pathomechanisms. For example, in an ex vivo model MMP2,
MMP3, and MMP9 led to an enhanced outflow facility, while
MMP1  concentrations  were  significantly  elevated  in
glaucomatous optic nerve heads [20,25]. Furthermore, in a
rodent  glaucoma  model  optic  nerve  ligation  led  to
significantly increased MMP9 concentrations in the retina
[27].
In the present study genotypes of the functional MMP1
−1607 1G/2G, MMP2 −1306 C/T, MMP2 −1575 G/A, and
MMP9  Q279R  polymorphisms  were  determined  in  322
patients with POAG, 202 patients with XFG and 248 control
subjects.  No  significant  differences  were  found  in  the
genotype  distributions  or  allelic  frequencies  of  the
investigated  polymorphisms  between  patients  and  control
subjects. As the study has a statistical power of 0.80 to detect
odds ratios between 1.61 and 1.68 for the allelic variants of
TABLE 1. NUCLEOTIDE SEQUENCES, MELTING TEMPERATURE, AND PRODUCT SIZES.
Name of primer Nucleotide sequence Melting temperature Product size
MMP1-1607 1G/2G left 5'-tgccacttagatgaggaaatt g-3' 59.22 °C 127 bp
MMP1-1607 1G/2G right 5'-cctgttttctttctgcgtca-3' 59.05 °C  
MMP2-1306 C/T left 5'-tttttcatctctgggccatt-3' 59.50 °C 101 bp
MMP2-1306 C/T right 5'-gacttctgagctgagacctga-3' 57.30 °C  
MMP2-1575 G/A left 5'-gtctgaagcccactgagacc-3' 59.84 °C 121 bp
MMP2-1575 G/A right 5'-aggtcaggggctgaaagaat-3' 60.07 °C  
MMP9 R279Q A/G left 5'-caggacacacttgggggtta-3' 60.80 °C 136 bp
MMP9 R279Q A/G right 5'-gccttggaagatgaatggaa-3' 60.01 °C  
TABLE 2. CLINICAL CHARACTERISTICS OF PATIENTS WITH POAG AND CONTROLS.
Clinical characteristic Patients with POAG (n=322) Control subjects (n=248) Significance p-value
Mean age (±SD) 74.1±10.6 74.4±7.1 0.19
Range (years) 37.1–92.9 57.2–90.7  
Arterial hypertension* 194 (60.2) 146 (58.9) 0.80
Diabetes mellitus* 36 (11.2) 32 (12.9) 0.60
*Numbers are given as n (%).
TABLE 3. CLINICAL CHARACTERISTICS OF PATIENTS WITH XFG AND CONTROLS.
Clinical characteristic Patients with XFG (n=202) Control subjects (n=248) Significance p-value
Mean age (±SD) 75.1±7.1 74.4±7.1 0.15
Range (years) 50.3–87.0 57.2–90.7  
Arterial hypertension* 116 (57.4) 146 (58.9) 0.77
Diabetes mellitus* 20 (9.9) 32 (12.9) 0.38
       
*Numbers are given as n (%).
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1766the MMP1 −1607 1G/2G, MMP2 −1306 C/T, MMP2 −1575
G/A,  and  MMP9  Q279R  polymorphisms  in  patients  with
POAG and odds ratios between 1.71 and 1.77 in patients with
XFG,  respectively,  our  data  suggest  that  the  investigated
polymorphisms are unlikely major genetic risk factors for
POAG and XFG in Caucasian patients.
Remarkably,  investigating  the  association  between
exfoliation syndrome and XFG and the MMP1 −1607 1G/2G
polymorphism, Tsironi and coworkers [37] reported an allele
contrast of borderline significance for exfoliation syndrome
(OR=1.47;  95%CI:  1.03–2.10;  p=0.04),  but  not  for  XFG.
Ninety patients with exfoliation syndrome and 92 patients
with XFG were included in their study. Furthermore, Wang
and  coworkers  [34-36]  reported  a  significant  association
between  MMP9  Q279R  and  acute  primary  angle  closure
glaucoma in Taiwanese patients (OR=2.59; 95%CI: 1.71–
3.90; p=<0.001), albeit this result could not be replicated by
subsequent studies from Singapore and southern China.
According to their far-reaching impact on the protein
degradation of the ECM as well as on the interaction of cells
with their surrounding, regulation of MMPs is under tight
control and is achieved on different levels. Besides epigenetic
regulation  via  histone  modification  and  chromatin-
remodeling  complexes,  evidence  emerged  that  post-
translational  mechanisms  leading  to  altered  stability  of
mRNA are also involved [43]. For example, transforming
TABLE 4. GENOTYPE AND ALLELE FREQUENCIES IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA (POAG).
Single nucleotide
polymorphism Patients with POAG (n=322) Control subjects (n=248) p-value
MMP1 −1607 1G/1G 89 (27.6%) 60 (24.2%) 0.35
1G/2G 165 (51.2%) 131 (52.8%)  
2G/2G 68 (21.1%) 57 (23.0%)  
2G frequency 0.467 0.494 0.37
MMP2 −1306 C/C 187 (58.1%) 138 (55.6%) 0.56
C/T 111 (34.5%) 88 (35.5%)  
T/T 24 (7.5%) 22 (8.9%)  
T allele frequency 0.247 0.266 0.46
MMP2 −1575 G/G 185 (57.5%) 142 (57.3%) 0.96
G/A 117 (36.3%) 86 (34.7%)  
A/A 20 (6.2%) 20 (8.1%)  
A allele frequency 0.244 0.254 0.69
MMP9 rs17576 A/A 139 (43.2%) 102 (41.1%) 0.63
A/G 141 (43.8%) 120 (48.4%)  
G/G 42 (13.0%) 26 (10.5%)  
G allele frequency 0.349 0.347 0.93
         Numbers for genotypes are n (%).
TABLE 5. GENOTYPE AND ALLELE FREQUENCIES IN PATIENTS WITH OPEN ANGLE GLAUCOMA SECONDARY TO EXFOLIATION SYNDROME (XFG).
Single nucleotide
polymorphism Patients with XFG (n=202) Control subjects (n=248) p-value
MMP1 –1607 1G/1G 51 (25.2%) 60 (24.2%) 0.80
1G/2G 96 (47.5%) 131 (52.8%)  
2G/2G 55 (27.2%) 57 (23.0%)  
2G frequency 0.510 0.494 0.63
MMP2 −1306 C/C 107 (53.0%) 138 (55.6%) 0.57
C/T 80 (39.6%) 88 (35.5%)  
T/T 15 (7.4%) 22 (8.9%)  
T allele frequency 0.272 0.266 0.84
MMP2 −1575 G/G 109 (54.0%) 142 (57.3%) 0.48
G/A 82 40.6%) 86 (34.7%)  
A/A 11 (5.4%) 20 (8.1%)  
A allele frequency 0.257 0.254 0.91
MMP9 rs17576 A/A 88 (43.6%) 102 (41.1%) 0.60
A/G 83 (41.1%) 120 (48.4%)  
G/G 31 (15.3%) 26 (10.5%)  
G allele frequency 0.359 0.347 0.71
        
Numbers for genotypes are n (%).
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1767growth factor-beta (TGF-β) extends the half-life of mRNAs
of MMP2 and MMP9 significantly, thereby increasing MMP2
and  MMP9  concentrations  [44].  Furthermore,  MMPs  are
secreted as inactive proenzymes and can be activated by other
proteinases  including  active  MMPs  [19].  Ultimately,
inhibition of MMPs is accomplished by specific (i.e., tissue
inhibitor  of  metalloproteinases)  and  unspecific  (e.g.,  α2-
macroglobulin) inhibitors [45,46]. Thus, our finding that the
MMP1 −1607 1G/2G, MMP2 −1306 C/T, MMP2 −1575 G/A,
and MMP9 Q279R polymorphisms are not associated with an
increased  risk  for  POAG  or  XFG  does  not  exclude  a
substantial  role  of  MMP1,  MMP2,  and  MMP9  in  the
pathogenesis of POAG or XFG.
In conclusion, based on the results of the present study,
none  of  the  investigated  functional  polymorphisms  in
MMP1, MMP2, and MMP9 themselves are major risk factors
among Caucasian patients with POAG or XFG.
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